ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting
“The ASCO presentations on T-DM1 will expand the body of clinical data reported on this highly promising compound,” commented Daniel Junius, President and Chief Executive Officer. “On May 30, the final results will be presented from the ˜second-line plus' Phase II trial in HER2-positive metastatic breast cancer, which will build on the data previously reported from this trial. This presentation has been selected for the ˜Best of ASCO®' program and will include objective response, progression-free survival and duration of response data from this 112-patient study. A separate presentation on June 1 will provide expanded information on the relationship between HER2 expression and response to T-DM1.”
T-DM1 Presentations at the ASCO Annual Meeting
“A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): final results” (abstract #1017).
“Quantitative assessment of HER2 status and correlation with efficacy for patients with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)” (abstract #1003).
In addition to these presentations on T-DM1, an abstract (#e15625) on IMGN242 has been accepted by ASCO for publication (as submitted). IMGN242 is in Phase II testing for the treatment of gastric cancer expressing the CanAg antigen targeted by the compound.
The ASCO annual meeting is being held May 29-June 2, 2009 in Orlando, Florida. Abstracts and other information about ASCO and this meeting may be found at www.asco.org.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and linkage of potent cancer-cell killing agents (CKAs) to such antibodies. The Company's proprietary Targeted Antibody PayloadTM (TAP) technology consists of ImmunoGen's highly potent CKAs, which have been designed specifically for delivery by antibodies to cancer cells, and the Company's engineered linkers, which direct the activation of the CKA inside a cancer cell. Compounds utilizing the TAP technology are in clinical testing through ImmunoGen's own programs and its collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, T-DM1, is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of products, including trastuzumab-DM1, by our collaborators, including risks related to uncertainties around clinical trials conducted and their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2008 and other reports filed with the Securities and Exchange Commission.
Best of ASCO® is a registered trademark of the American Society of Clinical Oncology.
Contact: ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations
and Corporate Communications
Posted: May 2009